Checkpoint Capital L.P. Has $3.50 Million Position in Kymera Therapeutics, Inc. $KYMR

Checkpoint Capital L.P. trimmed its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 42.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,750 shares of the company’s stock after selling 45,241 shares during the period. Kymera Therapeutics comprises about 1.2% of Checkpoint Capital L.P.’s portfolio, making the stock its 9th largest position. Checkpoint Capital L.P.’s holdings in Kymera Therapeutics were worth $3,495,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC raised its stake in shares of Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after purchasing an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after purchasing an additional 770 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Kymera Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after buying an additional 59,347 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the subject of a number of research reports. Oppenheimer increased their price objective on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. B. Riley Financial boosted their target price on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. UBS Group upped their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Piper Sandler raised their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, HC Wainwright lifted their price objective on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $79.03 on Friday. The stock’s 50-day simple moving average is $79.21 and its 200 day simple moving average is $68.32. The company has a market cap of $6.45 billion, a P/E ratio of -21.48 and a beta of 2.20. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) EPS. The business’s revenue was down 60.8% on a year-over-year basis. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jared Gollob sold 5,613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $499,164.09. Following the completion of the sale, the insider owned 122,029 shares of the company’s stock, valued at approximately $10,852,038.97. This represents a 4.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bruce Booth sold 81,866 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $90.13, for a total transaction of $7,378,582.58. Following the completion of the transaction, the director directly owned 675,341 shares of the company’s stock, valued at $60,868,484.33. This represents a 10.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 196,561 shares of company stock worth $17,097,428. Corporate insiders own 16.01% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.